ZW191 delivered a confirmed objective response rate of 61% at 6.4–9.6 mg/kg in platinum‑resistant ovarian cancer, with a 57% response rate in endometrial cancer at the same doses. Median duration of response was not reached at cutoff, median progression‑free survival across ovarian and endometrial cohorts was 7.6 months, and responses emerged quickly with a 1.4‑month median time to response. Disease control in the 6.4–9.6 mg/kg cohorts reached 100% across both indications, and activity was reported irrespective of folate receptor alpha expression. On safety, grade ≥3 treatment-emergent adverse events occurred in 55% of treated patients, led by neutropenia (24%), anemia (20%), and thrombocytopenia (12%); serious adverse events occurred in 35% of patients and 20% discontinued due to adverse events.
The core development is Zymeworks’ Phase 1 dose‑escalation readout for ZW191, an FRα‑targeted antibody‑drug conjugate with a novel topoisomerase‑1 payload, presented at AACR. The agent was administered up to 11.2 mg/kg. Part 2a, a dose‑optimization cohort in ovarian cancer at 6.4 and 9.6 mg/kg, has completed global enrollment and will set the recommended dose for subsequent registration‑directed studies.
Strategically, Zymeworks is aiming to differentiate in a field recalibrated by the approval of an FRα‑directed ADC restricted to high FRα expressers. By emphasizing responses regardless of FRα expression level and highlighting a bystander‑active topo‑1 payload, the company is signaling a bid to expand the eligible population and reduce reliance on stringent IHC thresholds that drive screen failure and operational friction. The trade‑off is clear: broader activity claims will invite regulatory pressure to define a companion diagnostic strategy or to deliver randomized data that demonstrate benefit in low and heterogeneous expressers. The safety profile—dominated by hematologic toxicity and a 20% discontinuation rate—will also need dose and schedule refinements to sustain the efficacy‑tolerability balance at scale.
For sites, a potential all‑comer or lower‑threshold FRα approach could streamline accrual and cut pre‑screening waste, but will require robust hematologic monitoring, proactive growth factor use policies, and clear dose‑modification playbooks to manage neutropenia and anemia. Sponsors and CROs face design choices that determine the regulatory runway: a single‑arm, enrichment‑based approach aimed at accelerated approval in a biomarker‑defined subgroup versus a faster pivot to randomized comparisons against chemotherapy or an active FRα comparator to secure a broader label. Diagnostic vendors and central labs should anticipate parallel efforts to validate FRα assays that capture heterogeneous expression and to correlate quantitative expression with outcomes, as regulators increasingly expect biomarker‑exposure‑response clarity for targeted ADCs. For patients, the early activity signal in both ovarian and endometrial cancers underscores a potential path in settings with limited options, provided durability and tolerability hold in larger cohorts.
Near‑term, the dose‑optimization readout will be the gating event for a registrational plan. Watch for whether Zymeworks maintains an expression‑agnostic posture or tightens eligibility to de‑risk regulatory review, and whether the next studies randomize against chemotherapy or include an Elahere‑containing control arm in ovarian cancer to test head‑to‑head differentiation. Safety surveillance in expansion—particularly for topo‑1 class liabilities such as interstitial lung disease—will be scrutinized, even if not prominent to date. Manufacturing scale‑up for a high‑DAR, novel‑payload ADC and any moves to align with a companion diagnostic partner will signal how quickly the program can convert an encouraging Phase 1 signal into a credible registration path across gynecologic tumors.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
